EVENT DESCRIPTION:
THE 21st CENTURY CURES ACT: Implications for Research and Drug Development
The passage of the 21st Century Cures Act has drawn both applause and criticism. A sweeping bipartisan effort with multiple components, the law dramatically boosts funding for medical research, particularly in areas such as cancer and brain disease. The law also relaxes regulatory processes for pharmaceuticals and medical devices. In doing so, the law’s supporters point to the potential for faster treatments benefiting from a streamlined approval process. Critics raise concerns that safety and efficacy might be compromised, with potentially devastating consequences. And the law also has been questioned for failing to explicitly address high drug prices, a growing public issue. These debates are unfolding as the Trump administration is expected to imminently announce its choice for a new FDA commissioner, who will head an agency directly impacted by the Cures act. In this Forum, experts will explore the implications of the law for biomedicine, regulation, pharmaceuticals and patient advocacy.
————————————————————————————- ENGAGE WITH US: Send our panelists questions in advance to [email protected] Tweet us @ForumHSPH #CuresAct WATCH THE LIVE WEBCAST ON OUR WEBSITE: https://theforum.sph.harvard.edu/events/the-21st-century-cures-act/ on Monday, February 27th, 2017, 12:30-1:30pm ET
————————————————————————————- EXPERT PARTICIPANTS:
Otis Brawley, Chief Medical Officer, American Cancer Society
Pamela Tenaerts, Executive Director of the Clinical Trials Transformation Initiative Jeffrey Drazen, Editor-in-Chief, The New England Journal of Medicine Aaron Kesselheim, Associate Professor of Medicine, Harvard Medical School/Brigham and Women’s Hospital, and Director of the Program On Regulation, Therapeutics, And Law
Moderated by Ed Silverman, Senior Writer and Pharmalot Columnist for STAT
————————————————————————————-
ADDITIONAL INFORMATION:
Part of: Policy Controversies
Presented jointly with STAT.
Image Credit: iStock.com/4X-image
